clinical trial · NCT07024693
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
Fuchs Endothelial Corneal DystrophyFuchsDT-168
brief summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
started
Jul 30, 2025
primary completion
Sep 1, 2026
completion
Dec 1, 2026
last updated
Dec 29, 2025
official title
A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol